Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, December 14, 2016

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions



Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review | BMC Medicine | Full Text
 

Conclusions

Most of the drugs that affect monoamine neurotransmitters licensed for the treatment of obesity over the past 65 years have been withdrawn because of adverse reactions.

0 comments :

Post a Comment

Your comments?